{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Papillary+Renal+Tumor",
    "query": {
      "condition": "Clear Cell Papillary Renal Tumor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Papillary+Renal+Tumor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:14:33.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00401128",
      "title": "Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-05",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-20",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401128"
    },
    {
      "nct_id": "NCT01120249",
      "title": "S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1545,
      "start_date": "2011-04-01",
      "completion_date": "2025-09-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 1002,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120249"
    },
    {
      "nct_id": "NCT00027820",
      "title": "Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia in Remission",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Myelodysplastic Syndrome",
        "Childhood Renal Cell Carcinoma",
        "Chronic Myelomonocytic Leukemia",
        "Clear Cell Renal Cell Carcinoma",
        "de Novo Myelodysplastic Syndrome",
        "Metastatic Renal Cell Cancer",
        "Previously Treated Myelodysplastic Syndrome",
        "Progression of Multiple Myeloma or Plasma Cell Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult Non-Hodgkin Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Refractory Anemia",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Renal Medullary Carcinoma",
        "Type 1 Papillary Renal Cell Carcinoma",
        "Type 2 Papillary Renal Cell Carcinoma",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 106,
      "start_date": "2001-08",
      "completion_date": "2004-09-05",
      "has_results": false,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Garland",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027820"
    },
    {
      "nct_id": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Kidney Medullary Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Papillary Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2020-07-29",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071223"
    },
    {
      "nct_id": "NCT05287945",
      "title": "Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Orellanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncorena AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-08-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287945"
    },
    {
      "nct_id": "NCT04413123",
      "title": "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papillary Renal Cell Carcinoma",
        "Unclassified Renal Cell Carcinoma",
        "Translocation Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Collecting Duct Renal Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Unresectable Advanced Renal Cell Carcinoma",
        "Metastatic Ncc Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bradley A. McGregor, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-11-05",
      "completion_date": "2026-12-20",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04413123"
    },
    {
      "nct_id": "NCT07243067",
      "title": "Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Cell Carcinoma",
        "Clear-cell Renal Cell Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Proteomic profiling of urinary EVs",
          "type": "OTHER"
        },
        {
          "name": "Blood sample collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 300,
      "start_date": "2026-07-15",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07243067"
    },
    {
      "nct_id": "NCT00035243",
      "title": "EPO906 Therapy in Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Neoplasms"
      ],
      "interventions": [
        {
          "name": "epothilone b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 53,
      "start_date": "2002-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-04-17",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035243"
    },
    {
      "nct_id": "NCT00001238",
      "title": "Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Cancer",
        "Urologic Malignant Disorders",
        "Renal Cell Carcinoma",
        "Familial Renal Cancer (FRC)",
        "Clear Cell Renal Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "1990-12-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001238"
    },
    {
      "nct_id": "NCT00726323",
      "title": "A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "foretinib (formerly GSK1363089 or XL880)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2006-06-30",
      "completion_date": "2010-08-18",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-05-22T04:14:33.305Z",
      "location_count": 12,
      "location_summary": "Greenbrae, California • San Francisco, California • Stanford, California + 9 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726323"
    }
  ]
}